Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
Catharina Korsukewitz, Stephen Reddel, Amit Bar‐Or, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 9, pp. 493-505
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Therapeutic Advances in Neurological Disorders (2021) Vol. 14
Open Access | Times Cited: 146
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
Srikanth Muppidi, Jeffrey T. Guptill, Saiju Jacob, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 12, pp. 970-971
Open Access | Times Cited: 113
COVID-19 Among Patients With Multiple Sclerosis
Mahdi Barzegar, Omid Mirmosayyeb, Mahsa Gajarzadeh, et al.
Neurology Neuroimmunology & Neuroinflammation (2021) Vol. 8, Iss. 4
Open Access | Times Cited: 98
Nanocarrier vaccines for SARS-CoV-2
Jatin Machhi, Farah Shahjin, Srijanee Das, et al.
Advanced Drug Delivery Reviews (2021) Vol. 171, pp. 215-239
Open Access | Times Cited: 92
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, et al.
Neurology Neuroimmunology & Neuroinflammation (2021) Vol. 8, Iss. 5
Open Access | Times Cited: 89
COVID-19 in ocrelizumab-treated people with multiple sclerosis
Richard A. Hughes, L Whitley, Kocho Fitovski, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 49, pp. 102725-102725
Open Access | Times Cited: 78
Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival
Michala Jakubíková, Michaela Týblová, Adam Tesař, et al.
European Journal of Neurology (2021) Vol. 28, Iss. 10, pp. 3418-3425
Open Access | Times Cited: 68
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Mona Sadat Mirtaleb, Amir Hossein Mirtaleb, Hassan Nosrati, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 138, pp. 111518-111518
Open Access | Times Cited: 60
Neuroimmune disorders in COVID-19
Helena Ariño, Rosie Heartshorne, Benedict Michael, et al.
Journal of Neurology (2022) Vol. 269, Iss. 6, pp. 2827-2839
Open Access | Times Cited: 50
Multiple sclerosis and COVID-19: interactions and unresolved issues
Ana Zabalza, Alan J. Thompson, Dalia Rotstein, et al.
The Lancet Neurology (2025) Vol. 24, Iss. 4, pp. 361-370
Closed Access | Times Cited: 1
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Diego Centonze, Maria A. Rocca, Claudio Gasperini, et al.
Journal of Neurology (2021) Vol. 268, Iss. 11, pp. 3961-3968
Open Access | Times Cited: 52
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement
Saúl Reyes, Anthony L. Cunningham, Tomáš Kalinčík, et al.
Journal of Neuroimmunology (2021) Vol. 357, pp. 577627-577627
Open Access | Times Cited: 48
Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies
Hui Ma, Qing-Zhu Yan, Jingru Ma, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 10, pp. 1295-1312
Open Access | Times Cited: 8
Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
Tobias Monschein, Hans‐Peter Hartung, Tobias Zrzavy, et al.
Journal of Neurology Neurosurgery & Psychiatry (2021) Vol. 92, Iss. 10, pp. 1033-1043
Open Access | Times Cited: 39
Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis
Klara Asplund Högelin, Nicolas Ruffin, Elisa Pin, et al.
iScience (2021) Vol. 24, Iss. 9, pp. 103078-103078
Open Access | Times Cited: 39
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
Tyler Smith, Maya Madhavan, Daniel Gratch, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 60, pp. 103735-103735
Open Access | Times Cited: 27
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
Verónica Cabreira, Pedro Abreu, Ricardo Soares-dos-Reis, et al.
Vaccines (2021) Vol. 9, Iss. 7, pp. 773-773
Open Access | Times Cited: 32
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
Fabio Buttari, Antonio Bruno, Ettore Dolcetti, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 52, pp. 102983-102983
Open Access | Times Cited: 30
MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register
Agni Konitsioti, Sarah Laurent, David Ellenberger, et al.
Journal of Neurology (2025) Vol. 272, Iss. 4
Open Access
The clinical risk and post-COVID-19 sequelae in patients with myasthenia gravis: a retrospective observational study
Chaoyue Zhang, Haocheng Luo, Yufei Deng, et al.
Frontiers in Neurology (2025) Vol. 16
Open Access
MAPPING THE SCIENTIFIC LITERATURE ON COVID-19 AND MENTAL HEALTH
Seema Gul, Shafiq Ur Rehman, Murtaza Ashiq, et al.
Psychiatria Danubina (2020) Vol. 32, Iss. 3-4, pp. 463-471
Open Access | Times Cited: 28
Neurological Effects of COVID-19 in Children
Tuhina Govil‐Dalela, Lalitha Sivaswamy
Pediatric Clinics of North America (2021) Vol. 68, Iss. 5, pp. 1081-1091
Open Access | Times Cited: 25
Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
Sara Esmaeili, Mohammad Hossein Abbasi, Meysam Abolmaali, et al.
BMC Neurology (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 24
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
Anoushka Lal, Yi Chao Foong, Paul G. Sanfilippo, et al.
Journal of Neurology (2024) Vol. 271, Iss. 9, pp. 5813-5824
Open Access | Times Cited: 3
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
Sedat Şen, Rana Karabudak, Irene Schiavetti, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 52, pp. 102968-102968
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top